1987
DOI: 10.2165/00003495-198700333-00013
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacokinetic Properties of Anisoylated Plasminogen Streptokinase Activator Complex and Other Thrombolytic Agents in Animals and in Humans

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
5
0

Year Published

1989
1989
2017
2017

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 28 publications
(6 citation statements)
references
References 7 publications
1
5
0
Order By: Relevance
“…Total fibrinolytic activity was measured as described by Been et al (1986) and Nunn et al (1987), and used as a functional bioassay of the plasma concentrations of the thrombolytic agents. The preparation of euglobulin fractions has been reported in detail elsewhere (Standring et al, 1988).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Total fibrinolytic activity was measured as described by Been et al (1986) and Nunn et al (1987), and used as a functional bioassay of the plasma concentrations of the thrombolytic agents. The preparation of euglobulin fractions has been reported in detail elsewhere (Standring et al, 1988).…”
Section: Methodsmentioning
confidence: 99%
“…In brief, plasma samples were diluted with 0.011% v/v acetic acid and the resulting precipitates were solubilized to give a 30-fold dilution of the original plasma. This dilution factor was found to abolish the interference from variable amounts of endogenous plasminogen and plasmin in the samples (Nunn et al, 1987). Fibrinolytic activity was assayed by the lysis of fibrin plates prepared from human fibrinogen (containing 2 ,ug plasminogen mg-' fibrinogen) incubated at 370 C for at least 18 h. The plates were stained with bromophenol blue and lysis zones were measured with an AMS image analyser.…”
Section: Methodsmentioning
confidence: 99%
“…The streptokinase-plasmin(ogen) complex formed by streptokinase in plasma is subject to neutralisation by plasma protease inhibitors, and this process contributes to its rapid clearance in vivo (3,4,7). Reversible, active centre acylation of the preformed complex in EMINASE* protects the molecule from inhibition (and also from autoproteolysis) and allows it to circulate for prolonged periods as a potentially active species (3)(4)(5)(6). Deacylation of the complex generates active material over a period of time determined by the deacylation rate of the agent, such that fibrinolysis is maintained for several hours (4,6,7).…”
Section: Lntroductionmentioning
confidence: 99%
“…In recent studies, the clearance of fibrinolytic activity has been quantified using a functional assay with a calibrated fibrin plate system. 18,19 Results from patients with AMI receiving the standard thera peutic dose of APSAC (30 U) indicated that the plas ma disappearance of activity was apparently monophasic with an average half-life (six patients) of approximately 90 minutes. 18 The disappearance half-life was independent of the pretreatment anti-SK antibody (IgG) level (Fig.…”
Section: Pharmacokineticsmentioning
confidence: 99%
“…Other recent work, using a func tional assay, also showed that the clearance of SK was rapid after infusion (1 hour) into patients with AMI. 5 APSAC was confirmed to be cleared much more slowly than SK-lys-plasmin(ogen) in guinea pigs and rabbits 19 (Table 1), and it is likely that the extended active half-life of APSAC in vivo is largely controlled by the rate of deacylation. This gain in bioavailability compared with SK and with other plasminogen activators such as t-PA 19 allows APSAC to be administered as a single injection without compromising the aims of complete throm bolysis and low incidence of reocclusion.…”
Section: Pharmacokineticsmentioning
confidence: 99%